Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Chronic pain is defined as 'an unpleasant sensory and emotional experience associated with actual or potential tissues damage, or described in terms of such damage". It is estimated that 1 in 5 Canadians experience chronic pain "Chronic pain is associated with the worst quality of life compared with other chronic diseases such as chronic lung or heart disease". Many of these problems are confined to a specific anatomic structure, and can be diagnosed and treated by injections, physical therapy, surgery, etc. Nonetheless, other individuals experience a more generalized pain. This condition has also resulted I depressed mood, bad relations with other people, sleep disturbances and poor quality of life.
The condition is very difficult to manage, and multiple methods have been recommended. Therapeutic intravenous infusion may be considered as one of these methods. Patients come for infusions of non-opioid medications under medical supervision and in a scheduled fashion. Two most commonly used mediation are lidocaine and ketamine.
Even though it is common to use multiple medications with complementary mechanisms of action to treat pain a combined lidocaine-ketamine infusion has never been studied Therefore, the purpose of this research study is to determine whether mixture of two medications (ketamine and lidocaine) infused intravenously 1 time per month for 6 months results in reduction of pain unpleasantness.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lidocaine-Ketamine Infusion | Experimental | Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lidocaine | Drug | Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Unpleasantness Score | Relative change on "Pain Unpleasantness Score". Moderate clinically important improvement is considered as 30% reduction. | Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Interference | Less Pain Interference measured by Short Form Brief Pain Inventory (SF-BPI) | Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Neuropathic Pain | Less Neuropathic pain measured by Self-Administered the Leads Assessment of Neuropathic Symptoms and Signs (S-LANSS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lisa Patterson, BA | Contact | 905-521-5100 | 74279 | pattersl@hhsc.ca |
| Name | Affiliation | Role |
|---|---|---|
| Michael Gofeld, MD, FRCPC | Michael G. DeGroote Pain Clinic, Hamilton Health Sciences | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008012 | Lidocaine |
| D007649 | Ketamine |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Ketamine | Drug | initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience |
|
| Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Functional Status | Improved Functional Status measured by Patient Self-Efficacy Questionnaire (PSEQ) | Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Emotional Status | Improved Emotional Status measured by Beck Depression Inventory (BDI), Pain Catastrophizing Scale (PCS) | Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Cognitive Status | No change in Cognitive Status measured by Montreal Cognitive Assessment (MoCA) | Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Quality of Life | Improved Quality of Life measured by Global Improvement and Satisfaction Score | Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Health Care Utilization | Less Health Care Utilization measured by Self-report of number of physician, clinic visits for other reason, emergency department visit and hospitalizations | Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Medication Use | Less Medication Use determined by Type and Dose of medications | Baseline, 1, 2, 3, 4, 5, 6 and 12 Months |
| Aniline Compounds |
| D000588 | Amines |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |